Related Experiment Video
Updated: Jun 14, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sreenath V Sharma1, Daniel A Haber, Jeff Settleman
1Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.
Abstract:
Efforts to discover new cancer drugs and predict their clinical activity are limited by the fact that laboratory models to test drug efficacy do not faithfully recapitulate this complex disease. One important model system for evaluating candidate anticancer agents is human tumour-derived cell lines. Although cultured cancer cells can exhibit distinct properties compared with their naturally growing counterparts, recent technologies that facilitate the parallel analysis of large panels of such lines, together with genomic technologies that define their genetic constitution, have revitalized efforts to use cancer cell lines to assess the clinical utility of new investigational cancer drugs and to discover predictive biomarkers.
Insights
Discovering new cancer drugs is challenging because lab models don't fully mimic the disease. However, advances in analyzing cancer cell lines and their genetics are improving drug efficacy testing and biomarker discovery.
Area of Science:
- Oncology
- Pharmacology
- Genomics
Background:
- Developing new anticancer drugs and predicting treatment success is hindered by laboratory models that do not accurately reflect cancer's complexity.
- Human tumor-derived cell lines are a key model system for evaluating potential anticancer agents.
- Cultured cancer cells can differ from in vivo tumors, posing challenges for efficacy assessment.
Purpose of the Study:
- To highlight the renewed potential of cancer cell lines for assessing investigational anticancer drugs.
- To emphasize the role of cell line analysis and genomic data in discovering predictive biomarkers for cancer therapy.
Main Methods:
- Utilizing large panels of human tumor-derived cell lines for parallel analysis.
- Employing genomic technologies to define the genetic makeup of cancer cell lines.
- Correlating cell line characteristics with drug efficacy and clinical utility.
Main Results:
- Recent technological advancements have revitalized the use of cancer cell lines in drug discovery.
- Parallel analysis of large cell line panels combined with genomic data enhances drug efficacy assessment.
- These approaches facilitate the discovery of biomarkers that predict patient response to cancer drugs.
Conclusions:
- Cancer cell lines, when analyzed with modern genomic and high-throughput methods, are valuable tools for anticancer drug development.
- Genomic characterization of cell lines aids in identifying predictive biomarkers for targeted cancer therapies.
- Improved preclinical models are crucial for advancing the clinical utility of novel cancer therapeutics.
